Login
search
Contact Us
NEWS

11th Asian & Oceanian Epilepsy Congress
Hong Kong, 2016

The resounding success of the 11th AOEC was echoed by the many participants of the Congress. It was a time and place not merely for academic exchange, but a venue for the experts, patients and family members alike to share their lives about facing epilepsy with one another. Caret image Read report

News from ILAE All news

EpilepsyDiagnosis.org now includes structural etiologies of the epilepsies

The structural etiology section of the EpilepsyDiagnosis.org diagnostic manual has been expanded to include details of major structural brain abnormalities that cause epilepsy, including the clinical context in which they occur, seizure types seen, EEG features, imaging features, genetic contributions, and differential diagnosis.

NEW Epilepsy Classification Roadmap

ILAE logo

The Classification of the Epilepsies moves forward – a roadmap for the development of an updated Classification is featured in Epilepsia Open. We present a framework to approach classification of patients in the clinic together with new concepts and terminology. We invite your comments for further refinement and consideration as we develop a Classification that will serve in clinical practice for the foreseeable future.


Caret imageMore news from ILAE

News Around the World All news

Advance notice of Trobalt®/Potiga® discontinuation

GlaxoSmithKline has made the decision to discontinue Trobalt/Potiga (retigabine/ezogabine) from all markets in which the product is currently available. Trobalt/Potiga will remain available to existing epilepsy patients until the end of June 2017 to enable identification of an appropriate alternative where required, after which the license will be withdrawn. In the meantime HCPs are being advised to start transitioning their patients off the medicine.


Swiss Epilepsy League supports innovative research project
Epilepsie-Liga unterstützt innovatives Forschungsprojekt

Jean-Marc Fritschy and Tilo Gschwind
Jean-Marc Fritschy (left) and Tilo Gschwind

The Swiss League Against Epilepsy announces Prof. Jean-Marc Fritschy and Tilo Gschwind of the University of Zurich have been awarded this year's Research Grant of CHF 25,000. With the help of innovative optogenetics, the researchers are investigating the development of epilepsy and paving the way for new treatment methods. Applications are now open for next year's grant for start-up funding for research projects for the advancement of experimental or clinical research in the field of epileptology.

Caret imageMore news around the world

Clinical Research News All news

New diagnostic criteria for neurocysticercosis: Reliability and validity

The diagnosis of neurocysticercosis (NCC) remains problematic due to the heterogeneity of its clinical, immunological, and imaging characteristics. A group of Latin American NCC experts developed by consensus a new set of diagnostic criteria for NCC. A multicenter, retrospective study was then conducted to validate it. These criteria have acceptable reliability and validity and could be a new tool for clinicians and researchers. Annals of Neurology DOI: 10.1002/ana.24732


WONOEP appraisal: Molecular and cellular biomarkers for epilepsy

Epilepsia

Peripheral biomarkers have myriad potential uses for treatment, prediction, prognostication, and pharmacovigilance in epilepsy. To date, no single peripheral biomarker has demonstrated proven effectiveness, although multiple candidates are in development. In this review, we discuss the major areas of focus including inflammation, blood-brain barrier dysfunction, redox alterations, metabolism, hormones and growth factors. Epilepsia. 4 July 2016. DOI: 10.1111/epi.13460

Caret imageMore clinical research news

Basic Science of Epilepsy News All news

Reducing premature KCC2 expression rescues seizure susceptibility and spine morphology in atypical febrile seizures

Atypical febrile seizures are considered a risk factor for epilepsy onset and cognitive impairments later in life. Patients with temporal lobe epilepsy and a history of atypical febrile seizures often carry a cortical malformation. This association has led to the hypothesis that the presence of a cortical dysplasia exacerbates febrile seizures in infancy, in turn increasing the risk for neurological sequelae. The authors' findings demonstrate that KCC2 overexpression in a compromised developing brain increases febrile seizure susceptibility and contribute to dendritic spine alterations. (Neurobiology of Disease doi:10.1016/j.nbd.2016.02.014)

Caret image Summary for non-specialists


Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus

GABAergic neurotransmission depends on KCC1 and NKCC2 Cl− co-transporters; a dysfunction in these co-transporters is seen in neonatal seizures. Bumetanide – a drug that blocks NKCC1 chloride cotransporters – has been shown to be beneficial in seizures in neonates. In the current study, the authors wanted to test whether bumetanide would be useful in status epilepticus (SE) by using brain slice electrophysiology and in vivo EEG experiments. Administration of bumetanide reduced seizure-like events induced by zero-Mg+², and in intact mice by administration of kainic acid. As seizures progressed, diazepam led to pharmacoresistance, which bumetanide was able to overcome. Hence, this study suggests that there might be a new indication of bumetanide in SE.

Caret image Summary for non-specialists

Caret imageMore basic science news

Home | Contact Us | Privacy & Security | Login | Sitemap
Creative Commons License
Text on this website is available under a
Creative Commons Attribution-ShareAlike 4.0 International License
except all videos and images, which remain copyrighted by the International League Against Epilepsy.